



Universiteit
Leiden
The Netherlands

In reply: neoadjuvant TKI study in early- and intermediate stage hepatocellular carcinoma

Osanto, S.; Woei-A-Jin, F.J.S.H.; Coenraad, M.J.; Weijl, N.I.; Burgmans, M.C.; Burggraaf, J.

Citation

Osanto, S., Woei-A-Jin, F. J. S. H., Coenraad, M. J., Weijl, N. I., Burgmans, M. C., & Burggraaf, J. (2022). In reply: neoadjuvant TKI study in early- and intermediate stage hepatocellular carcinoma. *The Oncologist*, 27(12), e977-e978. doi:10.1093/oncolo/oyac215

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](https://creativecommons.org/licenses/by-nc/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3486068>

Note: To cite this publication please use the final published version (if applicable).

In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma

Susanne Osanto^{1,2}, F.J. Sherida H. Woei-A-Jin,^{1,2,6} Minneke J. Coenraad,³ Nir I. Weijl,^{1,7} Mark C. Burgmans,⁴ Jacobus Burggraaf⁵

¹Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands

²Eindhoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands

³Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands

⁴Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands

⁵Center for Human Drug Research, Leiden, The Netherlands

⁶Present address: Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Belgium

⁷Present address: Haaglanden Medical Center Antoniushove, Leidschendam, The Netherlands

We appreciate the letter by Rizzo et al,¹ in which they acknowledged the important pharmacodynamic information obtained from our neoadjuvant phase II study of dovitinib prior to local/locoregional therapy in early- and intermediate-stage hepatocellular carcinoma (HCC).²

Although we agree that the observed rate of clinical benefit needs to be confirmed in a larger cohort, the safety of this novel treatment approach in an often frail patient population with limited cirrhotic liver metabolic capacity was a concern to us.³ We therefore designed a study with limited patient numbers in which we integrated a comprehensive panel of read-out methods to gain mechanistic insights in the effects of dovitinib in patients with HCC. The results may support the transition from early-stage research in small patient populations to larger studies plus future research of multi-receptor tyrosine kinase inhibitors (TKIs).

We share the authors' concern regarding underlying liver cirrhosis, particularly because subsequent locoregional treatments may result in loss of functional liver tissue. The authors also highlighted the risks of hepatotropic viral infections.⁴ We are aware that TKIs next to their anti-angiogenesis activity have also been shown to affect immune cell activity,^{5,6} and that dovitinib may exert similar immunomodulatory effects. In our cohort, 46% patients had HBV/HCV-associated HCC. All patients were closely monitored during the study period and follow-up, and hepatotropic virus activation was not observed in any patients.

We respectfully disagree with the comment of Rizzo et al. that the composition of the patient population ranging from BCLC 0 to B could have led to dilution of the effect of dovitinib and bias. Obviously, treatment response may differ between patients with different stages, but we consider dilution and bias not the appropriate terminology. As HCC, similar to other cancers, displays marked heterogeneity within the same stage of disease and between different clinical

disease stages, this could also argue in favor of testing a somewhat broader BCLC stage population to evaluate tolerability and pick-up early signs of efficacy, which is the goal of any explorative phase II trial. Although data on TKI activity in early-stage HCC are scarce and need to be formally proven, it is unlikely that drugs proven to be effective in advanced stages are ineffective in the neoadjuvant setting, especially for HCC where upregulation of actionable targets VEGFR2, PDGFR β , and FGFR1 has been shown not to differ significantly between BCLC stages A,




Figure 1. Median mRECIST response in 12 (very) early-stage HCC was higher than in 11 intermediate-stage HCC (–45% vs. –8%; $P = .0028$). The 2 very early (BCLC stage 0) patients are depicted in dark grey.

Received: 23 September 2022; Accepted: 23 September 2022.

© The Author(s) 2022. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

B, and C.⁷ Also, in our study, no statistically significant difference in plasma levels of pharmacodynamic VEGFR-pathway markers VEGF-A, VEGF-C, VEGF-D, PIGF, sVEGFR1, or sTIE2 were observed between patients with BCLC 0/A and BCLC B HCC. Furthermore, despite the very short treatment period, dovitinib induced mRECIST responses in both the BCLC 0/A group (9/12, 75%) and BCLC B group (2/11, 18%; Fig. 1). Absolute tumor shrinkage ≥ 1.5 cm was achieved in 9/12 BCLC 0/A and 4/11 BCLC B patients, whereas successful downstaging of 4/11 BCLC B patients allowed them to proceed to liver transplantation. Notwithstanding the small size of our study, the abovementioned data support efficacy of dovitinib in BCLC 0/A-B patients, though the efficacy may differ between groups.

We agree that evaluation of TKI bioactivity alone or in combination with other anticancer agents in early- and intermediate-stage HCC remains an important research aim. Currently ongoing trials evaluating TKIs, immune checkpoint inhibitors or combinations in neoadjuvant setting testify to the interest to further develop neoadjuvant treatment as an important treatment strategy to advance the HCC field.

Conflict of Interest

The authors indicated no financial relationships.

References

1. Rizzo A, Ricci AD, Brandi G. Neoadjuvant dovitinib in early- and intermediate-stage hepatocellular carcinoma. *Oncologist*. 2022;oyac168. <https://doi.org/10.1093/oncolo/oyac168>. Online ahead of print.
2. Woei-A-Jin FJSH, Weijl NI, Burgmans MC, et al. Neoadjuvant treatment with angiogenesis-inhibitor dovitinib prior to local therapy in hepatocellular carcinoma: A phase II study. *Oncologist*. 2021;26(10):854-864. <https://doi.org/10.1002/onco.13901>
3. Cheng AL, Thongprasert S, Lim HY, et al. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. *Hepatology*. 2016;64:774-784. <https://doi.org/10.1002/hep.28600>
4. Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of hbv reactivation during therapies for hcc: a systematic review. *Hepatology*. 2021;75:1257-1274. <https://doi.org/10.1002/hep.32241>
5. Ott PA, Adams S. Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. *Immunotherapy*. 2011;3:213-227. <https://doi.org/10.2217/imt.10.99>
6. Stehle F, Schulz K, Fahldieck C, et al. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. *J Biol Chem*. 2013;288:16334-16347. <https://doi.org/10.1074/jbc.M112.437962>
7. Kwon JH, Lee N, Park JY, et al. Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma. *PLoS One*. 2013;8:e64260. <https://doi.org/10.1371/journal.pone.0064260>